Obstacles to cardiovascular prevention in general practice

Acta Cardiologica

Volumn 59, Issue 2, 2004, Pages 119-125

  De Muylder, Régis ^a   Lorant, Vincent ^a   Paulus, Dominique ^a   Nackers, Fabienne ^a   Jeanjean, Michel ^a   Boland, Benoit ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b EPID 3034   (Belgium)

Author keywords

Cardiovascular prevention; General practice; Risk assessment

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL;

ADULT; AWARENESS; BELGIUM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EDUCATION; CLINICAL PRACTICE; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH SURVEY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MEDICAL RECORD; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIMARY PREVENTION; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SECONDARY PREVENTION;

AWARENESS; BELGIUM; CARDIOVASCULAR DISEASES; CLINICAL COMPETENCE; FAMILY PRACTICE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RISK ASSESSMENT;

EID: 1942504772     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.59.2.2005165     Document Type: Review

References (23)

1. Kornitzer M, De Bacquer D, De Backer G. Hypercholestérolé mie en Belgique, Année 1996: le point de vue de l'épidé miologiste (Hypercholesterolemia in Belgium anno 1996: view of the epidemiologist). Rev Med Brux 1997; 18: 16-25.
2. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434-1503.
3. Risk in cardiovascular disease [theme issue] BMJ 2000; 320: 659-724.
4. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokski E, Amouyel Ph, for the WHO MONICA Project. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 1999; 353: 1547-57.
5. De Henauw S, De Bacquer D, de Smet P, Kornitzer M, De Backer G. Trends in coronary heart disease in two Belgian areas: results from the MONICA Ghent-Charleroi study. J Epidemiol Community Health 1999; 53: 89-98.
6. EUROASPIRE Study group. A European Society of cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569-82.
7. EUROASPIRE II group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from Euroaspire II. Eur Heart J 2001; 22: 554-72.
8. EUROASPIRE I and II group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.
9. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, Wang CH, Heiss G. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998; 339: 861-7.
10. Grover SA, Lowensteyn I, Esrey K, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ 1995; 310: 975-8.
11. Barclay S, Todd C, Finlay I, Grande G, Wyatt P. Not another questionnaire! Maximizing the response rate, predicting non-response and assessing non-response bias in postal questionnaire studies of GPs. Fam Pract 2002; 19: 105-11.
12. Felder G, Eccles M, Gral R, Griffiths C, Grimthaw J. Using clinical guidelines. BMJ 1999; 318: 728-30.
13. Neaton JM, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Int Med 1992; 152: 1490-500.
14. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19 Suppl A:A2-11.
15. Enbergs A, Burger R, Reinecke H, Borggrefe M, Breithardt G, Kerber S. Prevalence of coronary artery disease in a general population without suspicion of coronary artery disease: angiographic analysis of subjects aged 40 to 70 years referred for catheter ablation therapy. Eur Heart J 2000; 21: 45-52.
16. van der Weijden T, Grol R, Schouten BJ, Knottnerus A. Barriers to working according to cholesterol guidelines: a randomized controlled trial on implementation of national guidelines in 20 general practices. Eur J Public Health 1998; 8: 113-18.
17. Muls E, De Backer G, De Bacquer D, Brohet C, Heller F. Lipi-Watch, a Belgian/Luxembourg survey on achievement of European Atherosclerosis Society Lipid Goals. Clin Drug Invest 2000; 19: 219-29.
18. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339-42.
19. Maher V, Sinfuego J, Pao P, Parekh J. Primary prevention of coronary heart disease. What has WOSCOPS told us and what questions remain? Drugs 1997; 54: 1-8.
20. Sherpherd J. Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study. Am J Cardiol 2001; 87: S19-22.
21. Rosenberg W, Donald A. Evidence-based medicine: an approach to clinical problem solving. BMJ 1995; 310: 1122-6.
22. McAlister FA, Graham I, Karr GW, Laupacis A. Evidence-based medicine and the practicing clinician. J Gen Intern Med 1999; 14: 236-42.
23. van der Weijden T, Dansen A, Schouten BJ, Knottnerus JA, Grol RP. Comparison of appropriateness of cholesterol testing in general practice with the recommendations of national guidelines: an audit of patient records in 20 general practices. Qual Health Care 1996; 5: 218-22.